These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 12460830)
21. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease. Pennell P; Leclercq B; Delahunty MI; Walters BA Clin Nephrol; 2006 Nov; 66(5):336-47. PubMed ID: 17140163 [TBL] [Abstract][Full Text] [Related]
22. Metabolic Dyslipidemia and Risk of Coronary Heart Disease in 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl. Rana JS; Liu JY; Moffet HH; Solomon MD; Go AS; Jaffe MG; Karter AJ Am J Cardiol; 2015 Dec; 116(11):1700-4. PubMed ID: 26428026 [TBL] [Abstract][Full Text] [Related]
23. Do Turkish adults really have lower serum levels of high-density lipoprotein cholesterol? Duran S; Memisogullari R; Coskun A; Yavuz O; Yuksel H Acta Cardiol; 2007 Oct; 62(5):453-9. PubMed ID: 17982965 [TBL] [Abstract][Full Text] [Related]
24. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Brousseau ME; O'Connor JJ; Ordovas JM; Collins D; Otvos JD; Massov T; McNamara JR; Rubins HB; Robins SJ; Schaefer EJ Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1148-54. PubMed ID: 12117730 [TBL] [Abstract][Full Text] [Related]
25. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Gotto AM Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414 [TBL] [Abstract][Full Text] [Related]
26. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Carey VJ; Bishop L; Laranjo N; Harshfield BJ; Kwiat C; Sacks FM Am J Cardiol; 2010 Sep; 106(6):757-63. PubMed ID: 20816113 [TBL] [Abstract][Full Text] [Related]
27. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Rubins HB; Robins SJ; Collins D; Iranmanesh A; Wilt TJ; Mann D; Mayo-Smith M; Faas FH; Elam MB; Rutan GH Am J Cardiol; 1995 Jun; 75(17):1196-201. PubMed ID: 7778538 [TBL] [Abstract][Full Text] [Related]
28. Screening for coronary heart disease risk in the elderly: total cholesterol versus high-density lipoprotein-cholesterol. Kligman EW; Watkins AJ Am J Prev Med; 1991; 7(5):263-7. PubMed ID: 1790030 [TBL] [Abstract][Full Text] [Related]
29. Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong. Ambegaonkar B; Chirovsky D; Tse HF; Lau YK; Tomlinson B; Li SK; Yue CS; Wong TH; Choi MC; Tunggal P; Sazonov V Adv Ther; 2012 May; 29(5):427-41. PubMed ID: 22562782 [TBL] [Abstract][Full Text] [Related]
30. Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Rana JS; Visser ME; Arsenault BJ; Després JP; Stroes ES; Kastelein JJ; Wareham NJ; Boekholdt SM; Khaw KT Int J Cardiol; 2010 Sep; 143(3):399-404. PubMed ID: 19394708 [TBL] [Abstract][Full Text] [Related]
31. Serum high density lipoprotein cholesterol levels in Chinese healthy subjects and patients with certain diseases. Cai HJ; Li ZX; Yang SM Atherosclerosis; 1982 Jun; 43(2-3):197-207. PubMed ID: 7115460 [TBL] [Abstract][Full Text] [Related]
32. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. Isles CG; Paterson JR QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551 [TBL] [Abstract][Full Text] [Related]
33. HDL and triglyceride as therapeutic targets. Fruchart JC; Duriez P Curr Opin Lipidol; 2002 Dec; 13(6):605-16. PubMed ID: 12441884 [TBL] [Abstract][Full Text] [Related]
34. Management of dyslipidemia in adults with diabetes. Haffner SM Diabetes Care; 1998 Jan; 21(1):160-78. PubMed ID: 9538988 [TBL] [Abstract][Full Text] [Related]
35. Pharmacologic treatment of type 2 diabetic dyslipidemia. Moon YS; Kashyap ML Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439 [TBL] [Abstract][Full Text] [Related]
37. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW; Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709 [TBL] [Abstract][Full Text] [Related]
38. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study. García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D; Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149 [TBL] [Abstract][Full Text] [Related]
39. Smoking and obesity make a bad problem worse: genetics and lifestyle affect high density lipoprotein levels in Turks. Hodoğlugil U; Mahley RW Anadolu Kardiyol Derg; 2006 Mar; 6(1):60-7. PubMed ID: 16524804 [TBL] [Abstract][Full Text] [Related]
40. Gender specific association of ABCA1 gene R219K variant in coronary disease risk through interactions with serum triglyceride elevation in Turkish adults. Çoban N; Onat A; Kömürcü Bayrak E; Güleç Ç; Can G; Erginel Ünaltuna N Anadolu Kardiyol Derg; 2014 Feb; 14(1):18-25. PubMed ID: 24084154 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]